STING1 and neoplasm: In terms of targeted therapies, combined treatment with cetuximab and STING agonists facilitated tumor recession in patients with HPV-positive (HPV+) head neck squamous cell carcinoma (HNSCC), which may depend on cetuximab-mediated NK cell activation and DC maturation [156].